{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:59:40Z","timestamp":1787662780291,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K07658"],"award-info":[{"award-number":["18K07658"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07663"],"award-info":[{"award-number":["21K07663"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s12149-021-01666-9","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T17:02:47Z","timestamp":1628442167000},"page":"1240-1252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood\u2013brain barrier"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4721-405X","authenticated-orcid":false,"given":"Jun","family":"Toyohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascalle","family":"Mossel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Wagatsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Tago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Imabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.","family":"Colabufo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Luurtsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,8]]},"reference":[{"key":"1666_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1602\/neurorx.2.1.63","volume":"2","author":"T Terasaki","year":"2005","unstructured":"Terasaki T, Ohtsuki S. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology, and methodology. NeuroRx. 2005;2:63\u201372.","journal-title":"NeuroRx"},{"key":"1666_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/clpt.2013.86","volume":"94","author":"KM Giacomini","year":"2013","unstructured":"Giacomini KM, Huang S-M. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther. 2013;94:3\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1666_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/1389200043489126","volume":"5","author":"CL Graff","year":"2004","unstructured":"Graff CL, Pollack GM. Drug transporter at the blood\u2013brain barrier and the choroid plexus. Curr Drug Metab. 2004;5:95\u2013108.","journal-title":"Curr Drug Metab"},{"key":"1666_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrn1728","volume":"6","author":"W L\u00f6scher","year":"2005","unstructured":"L\u00f6scher W, Potschka H. Drug resistance in brain disease and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591\u2013602.","journal-title":"Nat Rev Neurosci"},{"key":"1666_CR5","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.2174\/1381612822666160810150416","volume":"22","author":"M Feldmann","year":"2016","unstructured":"Feldmann M, Koepp M. ABC transporter and drug resistance in patients with epilepsy. Curr Pharm Des. 2016;22:5793\u2013807.","journal-title":"Curr Pharm Des"},{"key":"1666_CR6","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/epi.16581","volume":"61","author":"M Ilyas-Feldmann","year":"2020","unstructured":"Ilyas-Feldmann M, Asselin M-C, Wang S, McMahon A, Anton-Rodriguez A, Brown G, et al. P-glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)-[11C]verapamil PET. Epilepsia. 2020;61:1472\u201380.","journal-title":"Epilepsia"},{"key":"1666_CR7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/brain\/awh437","volume":"128","author":"HA Volk","year":"2005","unstructured":"Volk HA, L\u00f6scher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain. 2005;128:1358\u201368.","journal-title":"Brain"},{"key":"1666_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1476-5381.2012.01858.x","volume":"166","author":"FE O\u2019Brien","year":"2012","unstructured":"O\u2019Brien FE, Clarke G, Fitzgerald P, Dinan TG, Griffin BT, Cryan JF. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol. 2012;166:1333\u201343.","journal-title":"Br J Pharmacol"},{"key":"1666_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1017\/S1461145709009894","volume":"12","author":"OL de Klerk","year":"2009","unstructured":"de Klerk OL, Willemsen AT, Roosink M, Bartels AL, Hendrikse NH, Bosker FJ, et al. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood\u2013brain barrier. Int J Neuropsychopharmacol. 2009;12:895\u2013904.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1666_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1172\/JCI1269","volume":"101","author":"RB Kim","year":"1998","unstructured":"Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-protease inhibitors. J Clin Invest. 1998;101:289\u201394.","journal-title":"J Clin Invest"},{"key":"1666_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/febs.15148","volume":"287","author":"AB Chai","year":"2020","unstructured":"Chai AB, Leung GKF, Callaghan R, Gelissen IC. P-glycoprotein: a role in the export of amyloid-\u03b2 in Alzheimer\u2019s disease? FEBS J. 2020;287:612\u201325.","journal-title":"FEBS J"},{"key":"1666_CR12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2967\/jnumed.113.130161","volume":"55","author":"AK Deo","year":"2014","unstructured":"Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, et al. Activity of p-glycoprotein, a \u03b2-amyloid transporter at the blood\u2013brain barrier, is compromised in patients with mild Alzheimer disease. J Nucl Med. 2014;55:1106\u201311.","journal-title":"J Nucl Med"},{"key":"1666_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/brain\/awr298","volume":"135","author":"DME van Assema","year":"2012","unstructured":"van Assema DME, Lubberink M, Bauer M, van der Filer WM, Schuit RC, Windhorst AD, et al. Blood\u2013brain barrier P-glycoprotein function in Alzheimer\u2019s disease. Brain. 2012;135:181\u20139.","journal-title":"Brain"},{"key":"1666_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00702-008-0030-y","volume":"115","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, Willemsen ATM, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood\u2013brain barrier P-glycoprotein function in the progression of Parkinson\u2019s disease PSP and MSA. J Neural Transm (Vienna). 2008;115:1001\u20139.","journal-title":"J Neural Transm (Vienna)"},{"key":"1666_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/17425250903193079","volume":"5","author":"S Vautier","year":"2009","unstructured":"Vautier S, Fernandez C. ABCB1: the role in Parkinson\u2019s disease and pharmacokinetics of antiparkinsonian drugs. Expert Opin Drug Metab Toxicol. 2009;5:1349\u201358.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1666_CR16","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.2174\/1381612822666160810123634","volume":"22","author":"G Luurtsema","year":"2016","unstructured":"Luurtsema G, Elsinga P, Dierckx R, Boellaard R, van Waarde A. PET tracers for imaging of ABC transporters at the blood\u2013brain barrier: principles and strategies. Curr Pharm Des. 2016;22:5779\u201385.","journal-title":"Curr Pharm Des"},{"key":"1666_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cpt.73","volume":"97","author":"RM Raaphorst","year":"2015","unstructured":"Raaphorst RM, Windhorst AD, Elsinga PH, Colabufo NA, Lammertsma AA, Luurtsema G. Radiopharmaceuticals for assessing ABC transporters at the blood\u2013brain barrier. Clin Pharmacol Ther. 2015;97:362\u201371.","journal-title":"Clin Pharmacol Ther"},{"key":"1666_CR18","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.2174\/1381612822666160804093852","volume":"22","author":"M Lubberink","year":"2016","unstructured":"Lubberink M. Kinetic models for measuring P-glycoprotein function at the blood-brain barrier with positron emission tomography. Curr Pharm Des. 2016;22:5786\u201392.","journal-title":"Curr Pharm Des"},{"key":"1666_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nucmedbio.2004.06.007","volume":"32","author":"G Luurtsema","year":"2005","unstructured":"Luurtsema G, Molthoff CFM, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJF. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood\u2013brain barrier: kinetics and metabolism in the rat. Nucl Med Biol. 2005;32:87\u201393.","journal-title":"Nucl Med Biol"},{"key":"1666_CR20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0271678X16654493","volume":"37","author":"H Savolainen","year":"2017","unstructured":"Savolainen H, Windhorst AD, Elsinga PH, Cantore M, Colabufo NA, Willemsen AT, et al. Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood\u2013brain barrier in rats: kinetics, metabolism, and selectivity. J Cereb Blood Flow Metab. 2017;37:1286\u201398.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1666_CR21","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1021\/mp5008103","volume":"12","author":"H Savolainen","year":"2015","unstructured":"Savolainen H, Cantore M, Colabufo NA, Elsinga PH, Windhorst AD, Luurtsema G. Synthesis and preclinical evaluation of three novel fluorine-18 labeled radiopharmaceuticals for P-glycoprotein PET imaging at the blood\u2013brain barrier. Mol Pharm. 2015;12:2265\u201375.","journal-title":"Mol Pharm"},{"key":"1666_CR22","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1021\/acs.molpharmaceut.0c00514","volume":"17","author":"L Garc\u00eda-Varela","year":"2020","unstructured":"Garc\u00eda-Varela L, Arif WM, Garc\u00eda DV, Kakiuchi T, Ohba H, Harada N, et al. Pharmacokinetic modeling of [18F]MC225 for quantification of the P-glycoprotein function at the blood\u2013brain barrier in non-human primates with PET. Mol Pharm. 2020;17:3477\u201386.","journal-title":"Mol Pharm"},{"key":"1666_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05411-2","author":"L Garc\u00eda-Varela","year":"2021","unstructured":"Garc\u00eda-Varela L, Garc\u00eda DV, Aguiar P, Kakiuchi T, Ohba H, Harada N, et al. Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05411-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1666_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13550-020-00674-6","volume":"10","author":"J Toyohara","year":"2020","unstructured":"Toyohara J, Sakata M, Tago T, Colabufo NA, Luurtsema G. Automated synthesis, preclinical toxicity, and radiation dosimetry of [18F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood\u2013brain barrier. EJNMMI Res. 2020;10:84.","journal-title":"EJNMMI Res"},{"key":"1666_CR25","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","volume":"40","author":"P Zanotti-Fregonara","year":"2013","unstructured":"Zanotti-Fregonara P, Lammertsma AA, Innis RB. Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013;40:1781\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1666_CR26","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2967\/jnumed.113.119891","volume":"54","author":"J Toyohara","year":"2013","unstructured":"Toyohara J, Sakata M, Oda K, Ishii K, Ito K, Hiura M, et al. Initial human PET studies of metabotropic glutamate receptor type 1 ligand 11C-ITMM. J Nucl Med. 2013;54:1302\u20137.","journal-title":"J Nucl Med"},{"key":"1666_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s13246-015-0419-5","volume":"39","author":"K Ito","year":"2016","unstructured":"Ito K, Sakata M, Oda K, Wagatsuma K, Toyohara J, Ishibashi K, et al. Comparison of dosimetry between PET\/CT and PET alone using 11C-ITMM. Austr Phys Eng Sci Med. 2016;39:177\u201386.","journal-title":"Austr Phys Eng Sci Med"},{"key":"1666_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejmp.2017.09.124","volume":"42","author":"K Wagatsuma","year":"2017","unstructured":"Wagatsuma K, Miwa K, Sakata M, Oda K, Ono H, Kameyama M, et al. Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET\/CT. Phys Med. 2017;42:203\u201310.","journal-title":"Phys Med"},{"key":"1666_CR29","first-page":"248","volume":"16","author":"AS Kirschner","year":"1975","unstructured":"Kirschner AS, Ice RD, Beierwaltes WH. Radiation dosimetry of 131I\u201319-iodo-cholesterol: the pitfalls of using tissue concentration data reply. J Nucl Med. 1975;16:248\u20139.","journal-title":"J Nucl Med"},{"key":"1666_CR30","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"1666_CR31","first-page":"1","volume":"37","author":"ICRP","year":"2007","unstructured":"ICRP. The 2007 recommendations of the international commission on radiological protection ICRP publication 103. Ann ICRP. 2007;37:1\u2013332.","journal-title":"Ann ICRP"},{"key":"1666_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s12149-019-01398-x","volume":"33","author":"J Toyohara","year":"2019","unstructured":"Toyohara J, Yamamoto H, Tago T. Searching for diagnostic properties of novel fluorine-18-labeled D-allose. Ann Nucl Med. 2019;33:855\u201365.","journal-title":"Ann Nucl Med"},{"key":"1666_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","volume":"10","author":"J Logan","year":"1990","unstructured":"Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time\u2013activity measurement applied to [N-11C-methyl]-(\u2013)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1666_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2967\/jnumed.118.210104","volume":"59","author":"S Auvity","year":"2018","unstructured":"Auvity S, Caill\u00e9 F, Marie S, Wimberley C, Bauer M, Langer O, et al. P-Glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood\u2013brain barrier: a PET study on nonhuman primates. J Nucl Med. 2018;59:1609\u201315.","journal-title":"J Nucl Med"},{"key":"1666_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2967\/jnumed.118.219972","volume":"60","author":"N Tournier","year":"2019","unstructured":"Tournier N, Bauer M, Picher V, Nics L, Klebermass E-M, Bamminger K, et al. Impact of P-glycoprotein function on the brain kinetics of the weak substrate 11C-metoclopramide assessed with PET imaging in humans. J Nucl Med. 2019;60:985\u201391.","journal-title":"J Nucl Med"},{"key":"1666_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/FJC.0000000000000536","volume":"70","author":"F Fusi","year":"2017","unstructured":"Fusi F, Durante M, Gorelli B, Perrone MG, Colabufo NA, Saponara S. MC225, a novel probe for P-glycoprotein PET imaging at the blood\u2013brain barrier: in vitro cardiovascular safety evaluation. J Cardiovasc Pharmacol. 2017;70:405\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1666_CR37","first-page":"365","volume":"53","author":"E Brzezi\u0144ska","year":"1996","unstructured":"Brzezi\u0144ska E. Synthesis and pharmacological properties of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives. Acta Pol Pharm. 1996;53:365\u201371.","journal-title":"Acta Pol Pharm"},{"key":"1666_CR38","first-page":"1","volume":"22","author":"ICRP","year":"1992","unstructured":"ICRP. Radiological protection in biomedical research. ICRP Publication 62. Ann ICRP. 1992;22:1\u201318.","journal-title":"Ann ICRP"},{"key":"1666_CR39","unstructured":"RDRC Final Guidance: human research without an investigational new drug application. 2010 https:\/\/www.fda.gov\/media\/76286\/download. (Accessed Aug 2010)."},{"key":"1666_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-60761-416-6_10","volume":"596","author":"F Staud","year":"2010","unstructured":"Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of P-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol. 2010;596:199\u2013222.","journal-title":"Methods Mol Biol"},{"key":"1666_CR41","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.neurobiolaging.2008.02.002","volume":"30","author":"A Bartels","year":"2009","unstructured":"Bartels A, Kortekaas R, Bart J, Willemsen ATM, de Klerk OL, de Vries JJ, et al. Blood\u2013brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. 2009;30:1818\u201324.","journal-title":"Neurobiol Aging"},{"key":"1666_CR42","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00228-009-0709-5","volume":"65","author":"M Bauer","year":"2009","unstructured":"Bauer M, Karch R, Neumann F, Abrahim A, Wagner CC, Kletter K, et al. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil PET. Eur J Clin Pharmacol. 2009;65:941\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"1666_CR43","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.neurobiolaging.2015.05.020","volume":"36","author":"C Chiu","year":"2015","unstructured":"Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer\u2019s disease: preliminary observations. Neurobiol Aging. 2015;36:2475\u201382.","journal-title":"Neurobiol Aging"},{"key":"1666_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.clpt.2006.02.004","volume":"79","author":"R Toornvliet","year":"2006","unstructured":"Toornvliet R, van Berckel BNM, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, et al. Effect of age on functional P-glycoprotein in the blood\u2013brain barrier measured by use of (R)-[11C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1666_CR45","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s11307-012-0556-0","volume":"14","author":"DME van Assema","year":"2012","unstructured":"van Assema DME, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, et al. P-glycoprotein function at the blood\u2013brain barrier: effects of age and gender. Mol Imaging Biol. 2012;14:771\u20136.","journal-title":"Mol Imaging Biol"},{"key":"1666_CR46","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1208\/s12248-014-9625-4","volume":"16","author":"L Kervezee","year":"2014","unstructured":"Kervezee L, Hartman R, van den Berg D-J, Shimizu S, Emoto-Yamamoto Y, Meijer JH, et al. Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain. AAPS J. 2014;16:1029\u201337.","journal-title":"AAPS J"},{"key":"1666_CR47","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1208\/s12248-016-9973-3","volume":"18","author":"H Savolainen","year":"2016","unstructured":"Savolainen H, Meerlo P, Elsinga PH, Windhorst AD, Dierckx RAJO, Colabufo NA, et al. P-glycoprotein function in the rodent brain displays a daily rhythm, a quantitative in vivo PET study. AAPS J. 2016;18:1524\u201331.","journal-title":"AAPS J"},{"key":"1666_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/tpj.2016.74","volume":"18","author":"J Vendelbo","year":"2018","unstructured":"Vendelbo J, Olesen RH, Lauridsen JK, Rungby J, Kleinman JE, Hyde TM, et al. Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians. Pharmacogenomics J. 2018;18:121\u20136.","journal-title":"Pharmacogenomics J"},{"key":"1666_CR49","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.2174\/1381612826666200325110014","volume":"26","author":"WA Banks","year":"2020","unstructured":"Banks WA. The blood\u2013brain barrier interface in diabetes mellitus: dysfunctions, mechanisms and approaches to treatment. Curr Pharm Des. 2020;26:1438\u201347.","journal-title":"Curr Pharm Des"},{"key":"1666_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbi.2018.07.017","volume":"73","author":"SE Strock","year":"2018","unstructured":"Strock SE, Hartz AMS, Bernard J, Wolf A, Kachlmeier A, Mahringer A, et al. The concerted amyloid-beta clearance of LRP1 and ABCB1\/P-gp across the blood-brain barrier is linked by PICALM. Brain Behav Immun. 2018;73:21\u201333.","journal-title":"Brain Behav Immun"},{"key":"1666_CR51","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2174\/13816128113199990463","volume":"20","author":"L Sanchez-Covarrubias","year":"2014","unstructured":"Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des. 2014;20:1422\u201349.","journal-title":"Curr Pharm Des"},{"key":"1666_CR52","doi-asserted-by":"publisher","first-page":"7905486","DOI":"10.1155\/2017\/7905486","volume":"2017","author":"G Sita","year":"2017","unstructured":"Sita G, Hrelia P, Tarozzi A, Morroni F. P-glycoprotein (ABCB1) and oxidative stress: focus on Alzheimer\u2019s disease. Oxid Med Cell Longev. 2017;2017:7905486.","journal-title":"Oxid Med Cell Longev"},{"key":"1666_CR53","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fphar.2018.00658","volume":"9","author":"F Alasmari","year":"2018","unstructured":"Alasmari F, Ashby CR Jr, Hall FS, Sari Y, Tiwari AK. Modulation of the ATP-binding cassette B1 transporter by neuro-inflammatory cytokines: role in pathogenesis of Alzheimer\u2019s disease. Front Pharmacol. 2018;9:658.","journal-title":"Front Pharmacol"},{"key":"1666_CR54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.bbadis.2016.04.017","volume":"1863","author":"S Pugazhenthi","year":"2017","unstructured":"Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathway in obesity, diabetes, and Alzheimer\u2019s disease. Biochem Biophys Acta Mol Basis Dis. 2017;1863:1037\u201345.","journal-title":"Biochem Biophys Acta Mol Basis Dis"},{"key":"1666_CR55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3233\/JAD-160284","volume":"54","author":"EL Goldwaser","year":"2016","unstructured":"Goldwaser EL, Acharya NK, Sarkar A, Godsey G, Nagele RG. Breakdown of the cerebrovasculature and blood\u2013brain barrier: a mechanistic link between diabetes mellitus and Alzheimer\u2019s disease. J Alzheimers Dis. 2016;54:445\u201356.","journal-title":"J Alzheimers Dis"},{"key":"1666_CR56","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm\u00f6ller J, Johne A, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1666_CR57","first-page":"1427","volume":"47","author":"A Takano","year":"2006","unstructured":"Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee Y-J, et al. Evaluation of in vivo P-glycoprotein function at the blood\u2013brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med. 2006;47:1427\u201333.","journal-title":"J Nucl Med"},{"key":"1666_CR58","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clpt.2005.04.011","volume":"78","author":"M Brunner","year":"2005","unstructured":"Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, M\u00fcller U, Wadsak W, et al. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther. 2005;78:182\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"1666_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05419-8","author":"P Mossel","year":"2021","unstructured":"Mossel P, Garc\u00eda-Varela L, Arif WM, van der Weijdan CWJ, Boersma HH, Willemsen ATM, et al. Evaluation of P-glycoprotein function at the blood\u2013brain barrier using [18F]MC225 PET. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05419-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1666_CR60","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00302","author":"L Garc\u00eda-Varela","year":"2021","unstructured":"Garc\u00eda-Varela L, Rodr\u00edguez-P\u00e9rez M, Custoida A, Moraga-Amaro R, Colabufo NA, Aguiar P, et al. In vivo induction of P-glycoprotein function can be measured with [18F]MC225 and PET. Mol Pharm. 2021. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00302.","journal-title":"Mol Pharm"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01666-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01666-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01666-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T01:38:37Z","timestamp":1633657117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01666-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,8]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01666-9","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,8]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were approved by the Ministry of Health, Labour and Welfare Certified Clinical Research Review Board, Tokyo Metropolitan Geriatric Medical Center (CRB3180026) and in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}